Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Asana BioSciences, LLC

http://www.asanabiosciences.com/

Latest From Asana BioSciences, LLC

Finance Watch: Q2 Ends, Q3 Begins With Latest Group Of VC Mega-Rounds

Private Company Edition: June ended with Formation Bio’s $372m series D round and July began with Beacon’s $170m series B. Also, Curie.Bio raised a $380m fund, Freeflow Ventures emerged with $90m across multiple funds and EvolutionaryScale raised a $142m seed round.

Financing Innovation

Leo Pharma Strengthens Dermatology Position With Second Eczema Win

The company reported positive topline results from a second trial of its topical pan-JAK inhibitor, delgocitinib, in chronic hand eczema.

Clinical Trials Business Strategies

Erasca Unveils First Clinical Candidates, Aims To Create A MAPK Clamp

Former Ignyta CEO’s well-funded Erasca obtained its first clinical-stage precision oncology candidates from NiKang and Asana, eyeing a first-in-class approach to RAS/MAPK-driven cancers.

Innovation Cancer

JT Gains World-First Topical JAK Inhibitor Approval

Latest new drug approvals in Japan include the first anywhere for a topical JAK inhibitor and also a marketing clearance for a new contender in the large prostate cancer space.

Japan Approvals
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register